title: Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
abstract: In this multinational, randomized, double-blind study, the efficacy and safety of a 5 day course of moxifloxacin 400 mg orally od was compared with that of a 7 day course of clarithromycin 500 mg orally bd. in 750 patients with acute exacerbations of chronic bronchitis, characterized by at least two of the symptoms: sputum purulence, increased sputum volume or increased dyspnoea. Seven days after the end of therapy, clinical cure was achieved for 89% (287 of 322) of efficacy-evaluable patients in the moxifloxacin group and 88% (289 of 327) of patients in the clarithromycin group (95% CI, -3.9%, 5.8%). At follow-up (21-28 days post-treatment), the continued clinical cure rates were 89% (256 of 287) for moxifloxacin and 89% (257 of 289) for clarithromycin. A total of 342 pathogenic bacteria were isolated from the sputum of 287 patients. The most common pathogens were Haemophilus influenzae (37%), Streptococcus pneumoniae (31%) and Moraxella catarrhalis (18%). Seven days post-treatment, a successful bacteriological response was obtained for 77% (89 of 115) of patients in the moxifloxacin group and 62% (71 of 114) of patients in the clarithromycin group, indicating superiority of moxifloxacin (95% CI, 3.6%, 26.9%). Both treatments were well tolerated with few adverse events. This study demonstrated that for the treatment of acute exacerbations of chronic bronchitis a 5 day course of moxifloxacin 400 mg od was clinically equivalent and bacteriologically superior to a 7 day course of clarithromycin 500 mg bd.
authors.affiliation: Royal Brompton Hospital and Imperial College of Science, Technology and Medicine, National Heart and Lung Institute, London, UK. r.wilson2@ic.ac.uk
authors.forename: R
authors.initials: R
authors.lastname: Wilson
authors.forename: R
authors.initials: R
authors.lastname: Kubin
authors.forename: I
authors.initials: I
authors.lastname: Ballin
authors.forename: K M
authors.initials: KM
authors.lastname: Deppermann
authors.forename: H P
authors.initials: HP
authors.lastname: Bassaris
authors.forename: P
authors.initials: P
authors.lastname: Leophonte
authors.forename: A J
authors.initials: AJ
authors.lastname: Schreurs
authors.forename: A
authors.initials: A
authors.lastname: Torres
authors.forename: B
authors.initials: B
authors.lastname: Sommerauer
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds; D001419:Bacteria / Q000302:isolation & purification; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011446:Prospective Studies; D011804:Quinolines
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D004917:Erythromycin; D000077266:Moxifloxacin